David Hutton

According to the company, cyclosporine ophthalmic solution 0.1% is the first and only cyclosporine-based product for treating the signs and symptoms of dry eye disease.

Researchers at Indiana University School of Medicine will focus on providing a foundation for developing a new glaucoma therapeutic by testing human neurons and a regenerative therapy to rescue visual neurons from dying preclinically in human eyes under glaucoma conditions.

According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.

According to the company, EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.

David Hutton of Ophthalmology Times talks with Derek Hodkey, CEO and president of Orbis International, about 2023 in review as well as plans for the company moving into 2024.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.

Researchers found the administration of the neuropeptide α–melanocyte–stimulating hormone promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

Albert S Jun, MD, PhD, comes to UVA from the Johns Hopkins University School of Medicine.

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

A specialist in the field of ophthalmology and gene therapy, Dr Girach’s appointment enhances SpliceBio’s leadership team as it accelerates lead program targeting Stargardt disease towards clinical development.

The company is announcing 3 market access partnerships with PhilRx, Apollo Care, and PARx Solutions, expanding US availability of the solution.

According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.

All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024. The MACs had identified certain procedures as investigational for glaucoma management in patients over the age of 18.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

The company announced plans to enroll 320 volunteers in the study. Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

Jeff Todd, CEO and president of Prevent Blindness spoke with the Ophthalmology Times team about diabetes-related eye disease awareness at this year's American Academy of Ophthalmology meeting.

Scientists have developed a versatile imaging system that will help diagnose pathologies in the eye fundus.

According to the company, the designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular degeneration.

By 2022, numbers of inspections remained well below prepandemic levels, with a 79 percent decrease in foreign inspections and a 35 percent decline in domestic inspections compared with 2019.

David Hutton of Ophthalmology Times talks with Stephen Slade, MD, about clinical results using the light adjustable lens from RXSight.

During a multidisciplinary meeting with FDA, based on preliminary results from an ongoing Phase 1/2 study, the company received alignment on key points of the Phase 3 study design.

Interventional eyelid procedures enabled by TearCare technology delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through 6 months.

David Hutton of Ophthalmology Times talks with Jay Katz, MD, CMO for Glaukos, and Steven R. Sarkisian, MD, about the Glaukos iDose travoprost implant.

According to the company, if approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME.

Physicians from the Harvard Medical School and the Kresge Eye Institute at Wayne State University in Detroit recently published details from the case.

According to the company, the NORSE EIGHT study is set to kick off during the first quarter of 2024 and the Biologics License Application in the US is likely by the end of 2024.

Ocugen says the Regenerative Medicine Advanced Therapy designation will "help expedite the development of new regenerative medicines."

The companies announced they will team up to enhance patient care and workflow efficiencies with a comprehensive dry eye assessment and relief platform.